Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00284154
Status:
COMPLETED
Last Update Posted:
2013-03-13
First Post:
2006-01-27
Brief Title:
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial involves the administration of the chemotherapeutic medication vinflunine Vinflunine is not approved by the FDA and is experimental in the treatment of extensive small cell lung cancer The purpose of this research trial is to study the effectiveness of vinflunine in patients with relapsed extensive small cell lung cancer evaluate the toxicity and evaluate how long the response to this drug lasts
Detailed Description:
Eligible patients will receive vinflunine as a 15-20 minute intravenous IVinfusion once every three weeks 21 days This three week treatment period is called a cycle Patients whose cancer has not grown or if it has decreased in size may receive up to 6 cycles of vinflunine Evaluation will be conducted every other cycle
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None